CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,974.00
-36.00 (-1.79%)
At close: Feb 27, 2026
Market Cap291.84B +20.8%
Revenue (ttm)100.41B +6.4%
Net Income-9.59B
EPS-80.33
Shares Out147.84M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,142,581
Average Volume1,363,804
Open2,030.00
Previous Close2,010.00
Day's Range1,970.00 - 2,055.00
52-Week Range1,678.00 - 3,345.00
Beta0.64
RSI45.81
Earnings DateMar 20, 2026

About CMG Pharmaceutical

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutic... [Read more]

Sector Healthcare
Founded 2001
Employees 223
Stock Exchange KOSDAQ
Ticker Symbol 058820
Full Company Profile

Financial Performance

In 2024, CMG Pharmaceutical's revenue was 99.10 billion, an increase of 5.53% compared to the previous year's 93.91 billion. Earnings were 2.69 billion, a decrease of -58.26%.

Financial Statements